Company intelligence / Profile preview

Consortium.AI

New York City, New York, USAconsortium.ai ↗

Ownership: Private
Development stage: Preclinical

Overview

Consortium.AI was established to accelerate the development of new therapies for rare/orphan diseases like Duchenne muscular dystrophy using advanced AI-driven molecule design. The company leverages Insilico Medicine's deep neural network technology for target identification/compound generation, with A2A Pharmaceuticals providing drug development expertise. As of the last update, no clinical-stage programs or published results were reported.[3][4]

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small moleculesAI-designed compounds
Industry: Biotech

Beyond the preview

Go deeper on Consortium.AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Consortium.AI.

Explore the full profile